Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 30:17:100536.
doi: 10.1016/j.conctc.2020.100536. eCollection 2020 Mar.

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Christian Pfister  1   2 , Valentin Harter  3 , Yves Allory  4 , François Radvanyi  5 , Stéphane Culine  6 ; VESPER Trial Investigators
Collaborators, Affiliations

Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial

Christian Pfister et al. Contemp Clin Trials Commun. .

Abstract

The main objective of the French GETUG/AFU V05 VESPER randomized phase III study was to assess the efficacy of dd-MVAC and GC in term of progression-free survival in patients for whom chemotherapy has been decided, before or after surgery. A total of 500 patients have been randomized in 28 reference centers. Inclusion criteria were urothelial carcinoma without neuro-endocrine variant, disease defined by a T2, T3 or T4a N0 (pelvic lymph node ≤ 10 mm on CT scan) M0 staging for patients receiving neoadjuvant chemotherapy or pT3 or pT4 or pN+ and M0 for patients receiving adjuvant chemotherapy. Secondary endpoints include overall survival, safety, response rate. The peri-operative chemotherapy schedule was experimental arm dd-MVAC for a total of 6 cycles versus standard arm GC 4 cycles. The toxicity was evaluated according to NCI CTCAE (v 4.0). The progression-free survival rate will be estimated at 3 years by the Kaplan-Meier method. All the patients will be followed for 5 years. The last patient was randomized in March 2018 and the primary endpoint results are expected for mid-2021. As the dd-MVAC schedule is associated with higher response rates in metastatic disease, the real question today is to confirm such benefit in the peri-operative setting, taking also in consideration the chemotherapy toxicity. Tomorrow, the challenge may be the best chemotherapy and immunotherapy association, the authors hope that final Vesper Trial results will help to determine the gold standard chemotherapy.

Keywords: Bladder cancer; Peri-operative chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests with the manuscript.

Figures

Fig. 1
Fig. 1
Participating centers of the GETUG/AFU V05 multicentre, randomised phase III trial.
Fig. 2
Fig. 2
Study procedures, schedule and parameters of the patients follow-up.
See this image and copyright information in PMC

References

    1. Stein J.P., Lieskovsky G., Cote R. Radical cystectomy in the treatment of invasive bladder cancer. Long-term results in 1054 patients. J. Clin. Oncol. 2001;19:666–675. - PubMed
    1. Shariat S.F., Karakiewicz P.I., Palapattu G.S. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder cancer Research Consortium. J. Urol. 2006;176:2414–2422. - PubMed
    1. Milowsky M.I., Rumble R.B., Booth C.M. Guideline on muscle invasive and metastatic bladder cancer. American society of clinical oncology clinical practice guideline endorsement. J. Clin. Oncol. 2016;34:1945–1952. - PubMed
    1. Witjes A., Lebret T., Comperat E.M. Updated 2016 EAU Guidelines on muscle invasive and metastatic bladder cancer. Eur. Urol. 2017;71:462–475. - PubMed
    1. Sternberg C.N., de Mudler P., Schornagel J.H. Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors. Eur. J. Canc. 2006;42:50–54. - PubMed